Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Chemotargets

Request full access

Chemotargets is a computationally-oriented biotech company

Barcelona, SpainFounded 2006Biotech & Life Sciences

About Chemotargets

Chemotargets, S.L. operates as a computationally-oriented biotechnology company, strategically positioned to de-risk and accelerate drug discovery and development for the biopharmaceutical industry. Founded in March 2006 by Dr. Jordi Mestres, the company originated as a spin-off from the Systems Pharmacology lab at the IMIM Hospital del Mar Medical Research Institute in Barcelona. Dr. Mestres, whose background includes a Ph.D. in Computational Chemistry and leadership roles at pharmaceutical companies like Organon, leveraged his extensive academic and industry experience to establish the firm. His work in systems chemical biology and drug discovery forms the scientific foundation of the company.

The company's business model initially centered on providing predictive analytics solutions and services to pharmaceutical companies, biotech firms, and research institutions. It generates revenue through the licensing of its software platforms and by offering consultancy services in drug safety, design, optimization, and repurposing. A significant milestone was the licensing of its CLARITY® technology, which defines the efficacy and safety profiles of new drugs, to the U.S. Food and Drug Administration (FDA). Recently, Chemotargets has initiated a strategic transformation to evolve into a biotechnology company that also develops its own novel medicines, with an initial focus on oncology. This transition involves forming strategic alliances with research centers to co-develop new therapies and create new spin-off entities.

Chemotargets' core offering is an integrated suite of software products and services designed to enhance the cost-efficiency and safety of new medicines. Its flagship platform, CLARITY®, is a key tool used by clients to assess the safety and efficacy profiles of drug candidates. The company has also developed ProSurfScan, an AI-driven technology that uses structure-based methods to identify and generate new bioactive molecules for therapeutic targets. This dual-platform approach allows for the simultaneous optimization of safety and efficacy. The company serves a range of personnel within client organizations, from medicinal chemists to clinical investigators. The services portfolio includes customized drug safety assessments, identifying new therapeutic uses for existing drugs (repurposing), and AI-driven drug design.

Source: Dealroom company data

At a glance

Status
Operational
Employees
29
Open positions
None listed
Dealroom signal
67.2/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Drug Development, Spinout, Biotech and Pharma, Hard Tech, Horizon Europe, DT and LS, 4YFN, 4YFN 2026
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Oct 2020 $12M $47M Undisclosed —
SPINOUT✓Other financing Mar 2006 $0 — Hospital del Mar Research Institute —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Chemotargets website traffic

Latest recorded traffic for Chemotargets is 1.7K monthly website visits, up 70% over the last three months. Chemotargets's team declined 9.4% over the past year.

Latest monthly visits1.7K 3-month web change+70% 1-year team growth-9.4%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Chemotargets in the Barcelona ecosystem

Live from Dealroom

The Chemotargets office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Other known investors1 additional known investor

  • Hospital del Mar Research Institute
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇪🇸 Spain93.1%
🇲🇽 Mexico3.5%
🇨🇭 Switzerland3.5%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Chemotargets on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Chemotargets’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.